Jung Hoon Lee1, Kyoung Rok Kim1, Yong Seung Lee2, Sang Won Han2, Kun Suk Kim3, Sang Hoon Song3, Minki Baek4, Kwanjin Park5. 1. Department of Urology, Seoul National University College of Medicine, Seoul, Korea. 2. Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. 3. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 4. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 5. Division of Pediatric Urology, Department of Urology, Seoul National University Childrens' Hospital, Seoul National University College of Medicine, Seoul, Korea.
Abstract
PURPOSE: Anticholinergics are a key element in treating neurogenic detrusor overactivity, but only limited data are available in the pediatric population, thus limiting the application to children even for oxybutynin chloride (OC), a prototype drug. This retrospective study was designed to provide data regarding the efficacy, tolerability, and safety of OC in the pediatric population (0-15 years old) with spinal dysraphism (SD). MATERIALS AND METHODS: Records relevant to OC use for neurogenic bladder were gathered and scrutinized from four specialized clinics for pediatric urology. The primary efficacy outcomes were maximal cystometric capacity (MCC) and end filling pressure (EFP). Data on tolerability, compliance, and adverse events (AEs) were also analyzed. RESULTS: Of the 121 patient records analyzed, 41 patients (34%) received OC at less than 5 years of age. The range of prescribed doses varied from 3 to 24 mg/d. The median treatment duration was 19 months (range, 0.3-111 months). Significant improvement of both primary efficacy outcomes was noted following OC treatment. MCC increased about 8% even after adjustment for age-related increases in MCC. Likewise, mean EFP was reduced from 33 to 21 cm H2O. More than 80% of patients showed compliance above 70%, and approximately 50% of patients used OC for more than 1 year. No serious AEs were reported; constipation and facial flushing consisted of the major AEs. CONCLUSIONS: OC is safe and efficacious in treating pediatric neurogenic bladder associated with SD. The drug is also tolerable and the safety profile suggests that adjustment of dosage for age may not be strictly observed.
PURPOSE: Anticholinergics are a key element in treating neurogenic detrusor overactivity, but only limited data are available in the pediatric population, thus limiting the application to children even for oxybutynin chloride (OC), a prototype drug. This retrospective study was designed to provide data regarding the efficacy, tolerability, and safety of OC in the pediatric population (0-15 years old) with spinal dysraphism (SD). MATERIALS AND METHODS: Records relevant to OC use for neurogenic bladder were gathered and scrutinized from four specialized clinics for pediatric urology. The primary efficacy outcomes were maximal cystometric capacity (MCC) and end filling pressure (EFP). Data on tolerability, compliance, and adverse events (AEs) were also analyzed. RESULTS: Of the 121 patient records analyzed, 41 patients (34%) received OC at less than 5 years of age. The range of prescribed doses varied from 3 to 24 mg/d. The median treatment duration was 19 months (range, 0.3-111 months). Significant improvement of both primary efficacy outcomes was noted following OC treatment. MCC increased about 8% even after adjustment for age-related increases in MCC. Likewise, mean EFP was reduced from 33 to 21 cm H2O. More than 80% of patients showed compliance above 70%, and approximately 50% of patients used OC for more than 1 year. No serious AEs were reported; constipation and facial flushing consisted of the major AEs. CONCLUSIONS:OC is safe and efficacious in treating pediatric neurogenic bladder associated with SD. The drug is also tolerable and the safety profile suggests that adjustment of dosage for age may not be strictly observed.
Authors: Israel Franco; Mark Horowitz; Richard Grady; Richard C Adams; Tom P V M de Jong; Kelly Lindert; Detlef Albrecht Journal: J Urol Date: 2005-01 Impact factor: 7.450
Authors: R A Edelstein; S B Bauer; M D Kelly; M M Darbey; C A Peters; A Atala; J Mandell; A H Colodny; A B Retik Journal: J Urol Date: 1995-10 Impact factor: 7.450
Authors: Nelson Bennett; Margie O'Leary; Ankur S Patel; Macrina Xavier; Janet R Erickson; Michael B Chancellor Journal: J Urol Date: 2004-02 Impact factor: 7.450
Authors: Patrick C Cartwright; Douglas E Coplen; Barry A Kogan; Weining Volinn; Eileen Finan; Gary Hoel Journal: J Urol Date: 2009-08-15 Impact factor: 7.450
Authors: Adam J Rensing; Konrad M Szymanski; Rosalia Misseri; Joshua D Roth; Shelly King; Katherine Chan; Benjamin M Whittam; Martin Kaefer; Richard C Rink; Mark P Cain Journal: Pediatr Nephrol Date: 2019-03-03 Impact factor: 3.714